Navigation Links
Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis
Date:6/14/2008

,16) In patients with thrombosis of unknown origin, PNH may be an underlying cause. (3,12)

Prior to approval of Soliris, there were no therapies specifically available for the treatment of PNH. PNH treatment was limited to symptom management through periodic blood transfusions, non-specific immunosuppressive therapy and, infrequently, bone marrow transplantations -- a procedure that carries considerable mortality risk. (4,17)

About Soliris

Soliris was approved in March 2007 by the U.S. Food and Drug Administration (FDA) as the first treatment for PNH, a rare, debilitating and life-threatening blood disorder defined by hemolysis, or the destruction of red blood cells. In June 2007, the European Commission (EC) also approved the use of Soliris for the treatment of patients with PNH. Soliris is the first therapy approved in Europe for the treatment of PNH and was the first medicinal product to receive EC approval under the EMEA Accelerated Assessment Procedure.

Important Safety Information

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, nasopharyngitis (a runny nose), back pain and nausea. Treatment with Soliris should not alter anticoagulant management because the effect of withdrawal of anticoagulant therapy during Soliris treatment has not been established.

The U.S. product label for Soliris also includes a boxed warning: "Soliris increases the risk of meningococcal infections. Vaccinate patients with a meningococcal vaccine at least two weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use. Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary." During clinical studies, two out of 196 vaccinated PNH patients treated with Soliris experienced a serious meningococcal infection.

Prior to beginning
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
2. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
4. Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH
5. Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
6. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
7. Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
8. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
9. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
10. Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
11. New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... for the fourth quarter of 2013 on Monday, February 3, ... release after the close of trading. (Logo: ... call to discuss the operating highlights and financial results for ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA),a leading developer ... it,will hold its 2010 Annual Meeting of Shareholders on Thursday, ... meeting will be held concurrently at No. 39,Shangdi Xi Road, Haidian ... St.,John,s, Antigua . All shareholders of record as of ...
... WASHINGTON , June 17 The chairman of ... the U.S. Food and Drug Administration (FDA) over its move toward ... "emergency contraceptive." In a June 17 letter to Dr. ... DiNardo of Galveston - Houston criticized the FDA,s ...
Cached Medicine Technology:Sinovac Schedules 2010 Annual Meeting of Shareholders 2Sinovac Schedules 2010 Annual Meeting of Shareholders 3Pro-Life Chair Voices 'Grave Concern' over FDA Plan to Approve Abortion Drug for 'Emergency Contraception' 2Pro-Life Chair Voices 'Grave Concern' over FDA Plan to Approve Abortion Drug for 'Emergency Contraception' 3Pro-Life Chair Voices 'Grave Concern' over FDA Plan to Approve Abortion Drug for 'Emergency Contraception' 4
(Date:4/24/2014)... Scientists from The University of Manchester have identified a ... them more open to treatment. , The study published ... way for the development of drugs to target cells ... team made the discovery whilst exploring the possible mechanisms ... to treat breast and colon cancer. , Dr Andrew ...
(Date:4/24/2014)... April 24, 2014 ,Take me out to ... slices and kale chips. The more likely culprits include ... , Unfortunately for children who play youth baseball, ... contributing to weight problems, according to researchers at Wake ... current online edition of Childhood Obesity , found ...
(Date:4/24/2014)... corresponding terminology, and the relevance of palliation in ... on randomized controlled trials (RCTs). This is the ... for Quality and Efficiency in Health Care (IQWiG), ... , Together with external experts, IQWiG analysed studies ... cancer, malignant melanoma, and pancreatic cancer. For this ...
(Date:4/24/2014)... awarded one of 30 grants from the National Cancer ... Site in its new National Clinical Trials Network ... of investigators charged with distributing resources in a more ... system reflects recommendations from a 2010 Institute of ... goals:, Faster design, launch, and completion of ...
(Date:4/23/2014)... by Massachusetts General Hospital (MGH) investigators may lead to ... a serious medical problem use of fecal material ... the Clostridium difficile ( C. difficile ) ... the journal Clinical Infectious Diseases , the researchers ... donors unrelated to patients was as successful in curing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Take the bat, leave the candy 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3
... theory that contemporary orgasms succor fertility found that women who ... than those that did not. The best way to get ... scientists have ascertained. ,Dr Cathy, from the School of ... age of 32. //The women were asked to go to ...
... sexual intercorse soon after delivery could jeopardize their lives. A ... occured because they indulged in sexual intercourse too soon after ... air embolisms, traveling to the heart and brain.The blood vessels ... upto 4 weeks to return to normal after birth. The ...
... females who are given a choice to select their partners ... research involves the humble fruit fly, but experts believe it ... from the University of Georgia, led by Dr Daniel Promislow, ... in a vial with one virgin female.// Some of the ...
... AIDS will surpass the Black Death as the world's worst ... AIDS do not get life prolonging drugs. The illness has ... 14,000 people are infected each day with HIV, which destroys ... living with AIDS will die, pushing the death toll beyond ...
... out a high number of operations have lower deaths rates ... a scientist at the Institute of Public Health in Cambridge, ... 12 hospitals carrying// out heart surgery on children from 1991 ... carrying out 120 open heart operations on children less than ...
... of countries where leprosy is still a health problem need ... curable disease, the World Health Organization (WHO) has said. Partners ... meeting in Brazil for their annual meeting. Brazil is one ... major public health issue. The others are India, Madagascar, Mozambique, ...
Cached Medicine News:
... a biocompatible, flexible, one-piece artificial cornea (keratoprosthesis) ... native cornea., ,The World Health Organisation (WHO) ... 10 million people worldwide, however only 100,000 ... shortfall is due to a combination of ...
PDA application providing complex evaluation and management coding rule interactive templates....
Provides access via PDA to determine whether imaging examinations are necessary based on symptons and which studies will generate the most information....
PDA-version of the leading portable drug reference....
Medicine Products: